Make your money go further for just 25p per day

Novacyt: shares take a beating

09/04/2021 · Novacyt SA (NCYT) 

AIM UK

Covid test image

AIM’s top performer in 2020 has fallen back to earth after a disappointing trading update. Are the shares now a bargain or is there more trouble ahead? We offer our thoughts on this amazing little business.


The share price of Novacyt (LON: NCYT), the clinical diagnostics specialist and AIM’s top performer in 2020, tumbled 40% today on news that it is dispute with Department of Health and Social Care (DHSC).

Background

On 29 September 2020, Novacyt announced a second supply contract with the DHSC for its exsig®COVID-19 Direct kits and other products. In an earlier trading update on 29 January 2021, it explained it was in active discussions with the DHSC regarding an…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Novacyt SA

Novacyt: shares take a beating

09/04/2021 · Company Insights

AIM’s top performer in 2020 has fallen back to earth after a disappointing trading update. Are…


Eclectic delights of AIM

24/03/2021 · Company Insights

Bonkers Bargains, new Covid tests, kettle controls, video game developers and franchised lettings – such are…


More Company Insights

Bonkers Bargain: Superdry is looking much more promising

06/05/2021 · Superdry

ESG financing facility first of many

​Stonking Small Caps: disrupting an aged profession

06/05/2021